Antiphospholipid Syndrome Clinical Trial
Official title:
Domain 1 of β2-Glycoprotein 1 Autoantibodies and Thrombin Generation Capacity in Patients With Antiphospholipid Antibodies
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by thromboembolic events or pregnancy complications associated with circulating antiphospholipid antibodies (aPL-Abs). APS diagnosis needs the presence of both clinical and serological criteria (SAPORRO criteria, updated with Sydney criteria in 2006). However, no correlation between laboratory assays and the clinical thrombosis risk in patients with aPL-Abs was observed as only few patients with aPL-Abs developed clinical manifestations. Thrombin generation assays (TGA) is a global coagulation test that may represent a certain interest to evaluate thrombosis risk as a high thrombin generation capacity seems to be an independent risk factor for recurrent thromboembolic events. Another point of interest to assess the thrombotic risk is the detection of autoantibodies recognizing domain 1 of β2Gp1 (aβ2GP1-dm1). These autoantibodies are strongly related correlated with thrombotic and pregnancy manifestations. Recently, a commercial chemiluminescence immunoassay (CLIA) for detection of aβ2GP1-dm1 became available on Acustar® analyzer (HemosIL Acustar®, Instrument Laboratory, Bedford, USA) to facilitate aβ2GP1-dm1 research. The aim of this study is to evaluate two additional laboratory assays to improve the correlation between laboratory assays and the clinical thrombosis risk in patients with antiphospholipid (APL): thrombin generation assay and aβ2GP1-dm1. Each biological result (Antibodies to Domain 1 (Dm1) of β2-Glycoprotein 1 (aβ2GP1-dm1) and Thrombin Generation Test (TGT) parameters: endogen thrombin potential (ETP), lag time and time to peak) will be compared to the history of clinical thrombosis (venous or arterial thrombosis and/or obstetrical complications such as defined by the Saporro criteria updated with Sydney criteria in 2006) for each patient.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Completed |
NCT00537290 -
A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome
|
Phase 2 | |
| Recruiting |
NCT00616317 -
Register for Pediatric Patients With Antiphospholipid Syndrome (APS): European Project Extended Internationally Study
|
||
| Recruiting |
NCT00198068 -
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
|
||
| Completed |
NCT00180817 -
Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.
|
||
| Completed |
NCT03682419 -
Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)
|
N/A | |
| Not yet recruiting |
NCT03303508 -
Measurement of Anti-dsDNA by Both CLIFT & ELISA
|
N/A | |
| Recruiting |
NCT04262492 -
International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants
|
||
| Withdrawn |
NCT00180778 -
Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05583305 -
Prevalence and Etiologies of Intracranial Stenosis in Patients With Antiphospholipid Syndrome
|
||
| Recruiting |
NCT05644210 -
Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE
|
||
| Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
| Completed |
NCT00674297 -
Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients
|
Phase 2 | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT06373003 -
Negative Antiphospholipid Syndrome: a Multicentric Study
|
||
| Recruiting |
NCT06373926 -
Evaluation of Cell Membrane Expression of Annexin A2 on Monocytes by Flow Cytometry in Primary Antiphospholipid Syndrome
|
N/A | |
| Recruiting |
NCT01818505 -
The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome
|
N/A | |
| Completed |
NCT00878137 -
Reliability of Point-of-care INR Measurements in Patients With Antiphospholipid-antibody Syndrome Treated With Warfarin
|
N/A | |
| Completed |
NCT01104337 -
Drug Interaction Between Paracetamol and Warfarin
|
Phase 4 | |
| Completed |
NCT05313048 -
Prospective Observational Study to Evaluate a Possible Change in APS Antibody Profiles After COVID-19 Infection or Vaccination
|